Blog | HemaCare

HemaCare T Cells Support Study on Cell Therapy Consistency

Oct 5, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Leukopak, Cancer, T Cells


A new publication by scientists at the Cell and Gene Therapy Catapult in the UK cites the use of HemaCare-sourced CD3+ T cells for their cancer immunotherapy research.

The successful commercialization of gene-modified cell therapies relies in part on being able to manufacture a consistent product. Many cell and gene therapy developers use lentiviral vector delivery systems to impart the therapeutic gene modifications necessary to making their therapies effective.

Read More

HemaCare Isolated Immune Cells Bring Quality To Your Doorstep

Mar 31, 2021 10:03:00 AM / by Nancy Andon, MSc posted in Leukopak, Immunotherapy (Immunology)


You wanted cell isolation – we delivered!

In 2021, the word isolation tends to have garnered a negative connotation. However, when a cell biologist thinks of isolation, specifically cell isolation, they think of it as a wonderful thing.

After all, isolated cells are a sought-after starting material that allows scientists to dive deeper into their research and accelerate their studies. At HemaCare, we heard your requests and can now deliver isolated immune cells from full leukopak collections to your doorstep!

Read More

HemaCare Leukopaks Used to Evaluate CAR T Cell Therapy Potency

Nov 3, 2020 9:03:00 AM / by Nancy Andon, MSc posted in Leukopak, CAR-T, T Cells


A recent independent publication cites using HemaCare leukopaks for their evaluation of a CAR T cell therapy’s antitumor potency.

As the CAR T cell therapy field continues to grow, developers seek to refine techniques that will improve both the safety and efficacy of this promising cancer immunotherapy strategy. Scientists at Juno Therapeutics (Celgene) have been working to improve the potency of a CD19-targeted CAR T therapeutic currently in phase 1 and 2 clinical trials.

Read More

Cryopreserved Leukopaks: Finding the Best Fit for Your Research Needs

Jul 7, 2020 10:03:00 AM / by Nancy Andon, MSc posted in Leukopak, GMP Cellular Therapeutics, Basic Research


The product your lab chooses to fulfill their research needs largely depends on the stage of development. Are you conducting early drug discovery research involving several different candidates? Perhaps your company is involved in translational research, considering a lead candidate for clinical studies? What is your research budget? Choosing the right starting material for a specific project is a critical decision, but one that can sometimes be daunting.

Read More

HemaCare Leukopaks Used for Production of Allogeneic CAR T cells

May 28, 2019 10:04:00 AM / by Nancy Andon, MSc posted in Leukopak, CAR-T, allogeneic


A study out of Research Triangle Park, North Carolina [1] cites using HemaCare leukopaks as the starting material for new research on allogeneic CAR T cells.  

As most people know, the cancer fighting technique known as CAR T cell therapy has been getting a lot of attention these days, due to some remarkably positive clinical trial results. Two different versions of CAR T therapy have now earned FDA approval, so it seems that this type of therapy will inevitably be expanded to meet the needs of a considerably wider patient population. There’s a fairly large obstacle standing in the way of this expectation, however. Most clinical trials to date have been based on CAR T cell treatment as an autologous therapy, with the starting materials coming straight from the patients themselves. The problem with this autologous model is that it’s difficult to implement on a commercial scale, due to the limited availability of starting material.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts